alignx component vector nti suite 8.0 Search Results


klebsiella pneumoniae subsp.pneumoniae trevisan  (ATCC)
99
ATCC klebsiella pneumoniae subsp.pneumoniae trevisan
Klebsiella Pneumoniae Subsp.Pneumoniae Trevisan, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alignx+component+vector+nti+suite+8%2E0/custom%4013883%4034134705?v=ATCC
Average 99 stars, based on 1 article reviews
klebsiella pneumoniae subsp.pneumoniae trevisan - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
nebuilder hifi dna assembly cloning kit  (New England Biolabs)
99
New England Biolabs nebuilder hifi dna assembly cloning kit
Nebuilder Hifi Dna Assembly Cloning Kit, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alignx+component+vector+nti+suite+8%2E0/custom%40e5520%4032313945?v=New+England+Biolabs
Average 99 stars, based on 1 article reviews
nebuilder hifi dna assembly cloning kit - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
constitutive cas9 vectors  (Addgene inc)
96
Addgene inc constitutive cas9 vectors
Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of <t>CRISPR-Cas9</t> mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)
Constitutive Cas9 Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alignx+component+vector+nti+suite+8%2E0/10__1158_slash_2159___8290__cd___21___1307-467-0-9?v=Addgene+inc
Average 96 stars, based on 1 article reviews
constitutive cas9 vectors - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
alignx  (InforMax Inc)
90
InforMax Inc alignx
Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of <t>CRISPR-Cas9</t> mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)
Alignx, supplied by InforMax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alignx+component+vector+nti+suite+8%2E0/us12012452-333-3-11?v=InforMax+Inc
Average 90 stars, based on 1 article reviews
alignx - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
alignx component vector nti suite 8.0  (InforMax Inc)
90
InforMax Inc alignx component vector nti suite 8.0
Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of <t>CRISPR-Cas9</t> mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)
Alignx Component Vector Nti Suite 8.0, supplied by InforMax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alignx+component+vector+nti+suite+8%2E0/us09206248-98-23-30?v=InforMax+Inc
Average 90 stars, based on 1 article reviews
alignx component vector nti suite 8.0 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
vector nti suite 8.0  (InforMax Inc)
90
InforMax Inc vector nti suite 8.0
Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of <t>CRISPR-Cas9</t> mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)
Vector Nti Suite 8.0, supplied by InforMax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alignx+component+vector+nti+suite+8%2E0/us09908937-328-7-11?v=InforMax+Inc
Average 90 stars, based on 1 article reviews
vector nti suite 8.0 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
phylogenetic analysis mac vector software package  (MacVector inc)
90
MacVector inc phylogenetic analysis mac vector software package
Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of <t>CRISPR-Cas9</t> mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)
Phylogenetic Analysis Mac Vector Software Package, supplied by MacVector inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alignx+component+vector+nti+suite+8%2E0/pmc03183768-54-35-32?v=MacVector+inc
Average 90 stars, based on 1 article reviews
phylogenetic analysis mac vector software package - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
dnaman  (Lynnon corporation)
90
Lynnon corporation dnaman
Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of <t>CRISPR-Cas9</t> mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)
Dnaman, supplied by Lynnon corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alignx+component+vector+nti+suite+8%2E0/10__1590_slash_s1415___47572008000300021-80-23-24?v=Lynnon+corporation
Average 90 stars, based on 1 article reviews
dnaman - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
pgem-t vector  (Promega)
90
Promega pgem-t vector
Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of <t>CRISPR-Cas9</t> mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)
Pgem T Vector, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alignx+component+vector+nti+suite+8%2E0/pm10037712-74-4-6?v=Promega
Average 90 stars, based on 1 article reviews
pgem-t vector - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
hindiii  (New England Biolabs)
99
New England Biolabs hindiii
Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of <t>CRISPR-Cas9</t> mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)
Hindiii, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alignx+component+vector+nti+suite+8%2E0/custom%40r0104%4010%2E3390%2Ff9110699?v=New+England+Biolabs
Average 99 stars, based on 1 article reviews
hindiii - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
mouse: nod-prkdcem26cd52 il2rgem26cd22 /njucrl (ncg) mice  (GemPharmatech Co Ltd)
90
GemPharmatech Co Ltd mouse: nod-prkdcem26cd52 il2rgem26cd22 /njucrl (ncg) mice
Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of <t>CRISPR-Cas9</t> mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)
Mouse: Nod Prkdcem26cd52 Il2rgem26cd22 /Njucrl (Ncg) Mice, supplied by GemPharmatech Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alignx+component+vector+nti+suite+8%2E0/10__1016_slash_j__isci__2024__111589-558-5-12?v=GemPharmatech+Co+Ltd
Average 90 stars, based on 1 article reviews
mouse: nod-prkdcem26cd52 il2rgem26cd22 /njucrl (ncg) mice - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
lenticas9 blast addgene  (Addgene inc)
96
Addgene inc lenticas9 blast addgene
Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of <t>CRISPR-Cas9</t> mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)
Lenticas9 Blast Addgene, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alignx+component+vector+nti+suite+8%2E0/pm37267951-227-166-167?v=Addgene+inc
Average 96 stars, based on 1 article reviews
lenticas9 blast addgene - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

Image Search Results


Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of CRISPR-Cas9 mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)

Journal: Cancer Discovery

Article Title: Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia

doi: 10.1158/2159-8290.cd-21-1307

Figure Lengend Snippet: Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of CRISPR-Cas9 mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)

Article Snippet: Constitutive Cas9 vectors (LentiV_Cas9_Puro vector, ref. 80; LentiCas9_Blast vector, Addgene 52962, ref. 81; a gift from Feng Zhang, Massachusetts Institute of Technology, Cambridge, MA) were used to generate Cas9expressing cells. sgRNAs were cloned into the LRG2.1T (82).

Techniques: Inhibition, CRISPR, Mutagenesis, Infection, Comparison, Sequencing